aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.
martes, 1 de septiembre de 2026
New guidelines on migraine prevention reflect increasing options for patients Since 2012, the FDA has approved a half dozen new medications By Isabella CuetoAug. 31, 2026 Chronic Disease Reporter
https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_138aT13bjrzopKXIlbkM30g3rgHkB6i8ewiBQfvOB5U9t-5jaxxSOgtGICE_HhvKxCsrDypD_P7nG7nGe-mCXlMuF9g&_hsmi=436432001&utm_content=436432001&utm_source=hs_email
New migraine guidelines highlight growing treatment options
The American Headache Society and the American Academy of Neurology released new migraine guidelines yesterday, the first time they've done so since 2012.
The groups gave high marks on efficacy and tolerability to AbbVie's Qulipta, Lundbeck's Vyepti, Amgen and Novartis' Aimovig, Teva's Ajovy, and Lilly's Emgality. They also recommended the drugs as a preventive option for patients who frequently rely on pain medication once their attacks begin.
Some experts, however, were concerned that the new guidelines are complicated and may scare off primary care doctors.
Can buying a drug patent application be seen as a bid to prolong a monopoly? Amgen and an insurer are battling over the answer, and the FTC has weighed in
https://www.statnews.com/pharmalot/2026/08/31/pending-drug-patent-applications-amgen-carefirst/
By Ed SilvermanAug. 31, 2026
Pharmalot Columnist, Senior Writer
The Trump administration is burying science and health care in paperwork Despite a stated focus on ‘finding efficiencies,’ the White House has increased the bureaucracy scientists, Medicaid beneficiaries must navigate
https://www.statnews.com/2026/09/01/white-house-science-medicaid-bureaucracy-paperwork/
By Abdullah Shihipar and Brandon D.L. MarshallSept. 1, 2026
Shihipar directs narrative projects and policy impact initiatives at the People, Place, and Health Collective at the Brown University School of Public Health. Marshall is a professor of epidemiology at the Brown University School of Public Health, and director of the People, Place, and Health Collective.
Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more President Trump has announced the next round of pricing deals with drugmakers
https://www.statnews.com/pharmalot/2026/09/01/novartis-bristol-trials-paused-pancreatic-cancer-drug-price-pharmalittle-newsletter/
By Andrew JosephSept. 1, 2026
Europe Correspondent
Trump strikes nine more deals with drugmakers to lower prices Many details of agreements with the companies remain unclear By Daniel Payne and Elaine ChenAug. 31, 2026
https://www.statnews.com/2026/08/31/trump-most-favored-nation-drug-pricing-new-round-price-cuts-announced/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz--IAmaiNKoQUxkxAMKF-aFvX79Gyhz_zRr5c29Z-lLFc7eoZhZcgzeLjjeQ6hoDr956Q4hHqdK94P-5sD--kp74M_sCxw&_hsmi=436432001&utm_content=436432001&utm_source=hs_email
Trump strikes more drug pricing deals with biotechs
President Trump yesterday announced that his administration has made deals with nine new companies, joining the 17 that it previously struck agreements with.
The new companies are: Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB. The agreements are similar to the earlier ones — to sell new medications to U.S. patients at prices comparable to the lowest prices in peer countries, and to offer their drugs to Medicaid at “most-favored nation” prices.
But also like the earlier deals, the details of these agreements have not been released and it's unclear what the impact on overall drug costs will be.
Fact vs misinformation: An official EU guide to GMOs and gene-edited foods European Parliament | September 1, 2026
https://geneticliteracyproject.org/2026/09/01/fact-vs-misinformation-an-official-eu-guide-to-gmos-and-gene-edited-foods/
The rules governing new gene editing techniques for plants – called “new genomic techniques” (NGTs) – are being changed at EU level. Gene-edited plants will be divided into two categories, depending on the type and number of edits involved. Those with few genetic changes that could have occurred through conventional breeding techniques will be considered conventional plants, while the rest will have to follow the same strict rules as GMOs.
‘Right-to-try’: Montana’s new law allows licensed center for therapies not yet approved by FDA Washington Post | September 1, 2026
https://geneticliteracyproject.org/2026/09/01/right-to-try-montanas-new-law-allows-licensed-center-for-therapies-not-yet-approved-by-fda/
Montana has become the first state to license clinics that can sell access to experimental treatments still working through the FDA’s approval pipeline — a striking expansion of the “right-to-try” movement, reports Vicki Norton for The Washington Post.
African science innovation is growing exponentially, but it’s almost entirely absent from Wikipedia. Why that’s a problem. SciDev.Net | September 1, 2026
https://geneticliteracyproject.org/2026/09/01/african-science-innovation-is-growing-exponentially-but-its-almost-entirely-absent-from-wikipedia-why-thats-a-problem/
Africa’s scientific output is surging, but you’d barely know it from Wikipedia: the continent accounts for roughly 10 percent of the site’s articles, yet science and technology topics make up less than 1 percent, as Duncan Mboya reports for SciDev.Net.
Five alarming ways ‘autonomous AI’ can go rogue New York Times | September 1, 2026
https://geneticliteracyproject.org/2026/09/01/five-alarming-ways-autonomous-ai-can-go-rogue/
In July 2026, Hugging Face discovered a cyberattack unlike any it had seen before — only to learn the culprit wasn’t a human hacker but a swarm of OpenAI’s own AI agents that had broken loose during a routine security test, as the The New York Times’ Dylan Freedman reports. Over months, the agents escaped their sandboxes, taught themselves to cooperate, and quietly hacked both OpenAI’s and Hugging Face’s systems for weeks before anyone caught on.
Politicizing science: Trump’s pick to head the FDA—Heidi Overton— promotes an ‘alternative system’ of ‘conservative-based science’ Scientic American | September 1, 2026
https://geneticliteracyproject.org/2026/09/01/politicizing-science-trumps-pick-to-head-the-fda-heidi-overton-promotes-an-alternative-system-of-conservative-based-science/
President Trump’s nominee to run the Food and Drug Administration once called for conservatives to build their own scientific journals and steer research funding toward right-wing policy goals, as Scientific American’s Adam Kovac reports.
Viewpoint: Follow the money: How Bloomberg Philanthropies and the NGO Lighthouse Reports manufactured a Big Food safety scandal David Zaruk | August 31, 2026
https://geneticliteracyproject.org/2026/08/31/viewpoint-heres-how-bloomberg-philanthropies-funded-lighthouse-reports-cynically-twisted-the-data-to-prove-big-food-is-trying-to-block-safety-measures/
What happens when you want to run a campaign, but you have very limited data and evidence? One strategy more increasingly used is to hire an activist NGO like Lighthouse Reports to fabricate an investigation they can funnel through their tried and tested noise machine. What happens if the budget has been cleared but there is no story? No problem. Lighthouse Reports has experienced spinmeisters capable of communicating insignificant research like it was a groundbreaking exposé. Just pay the Dutch NGO enough and they’ll deliver?
Viewpoint— ‘Only when it agrees with him’: How RFK Jr. bullies journals that run research that contradicts his anti-vaccine ideology Shelby Bradford | September 1, 2026
https://geneticliteracyproject.org/2026/09/01/viewpoint-only-when-it-agrees-with-him-how-rfk-jr-bullies-journals-that-run-research-that-contradicts-his-anti-vaccine-ideology/
The U.S. Secretary for Health and Human Services is once again questioning a publisher on an editorial action regarding a paper on vaccination.
FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels FDA Drug Safety Communication – September 1, 2026
https://www.fda.gov/drugs/drug-safety-communications/fda-adds-boxed-warning-labeling-ferric-carboxymaltose-injection-injectafer-describe-risk-low?utm_medium=email&utm_source=govdelivery
FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels
The Food and Drug Administration has approved revisions to the labeling for ferric carboxymaltose injection (currently marketed as Injectafer) that adds a boxed warning, the agency’s most prominent safety warning. This boxed warning describes the risk for symptomatic hypophosphatemia (low levels of phosphate in the blood) associated with ferric carboxymaltose injection and recommends phosphate monitoring in patients at risk of hypophosphatemia and in any patient who receives a repeat course of therapy within three months of the prior course.
Clinical manifestations depend on the severity and duration of hypophosphatemia. Symptoms may include muscle weakness or pain, fatigue, tremors, confusion, seizures, and cardiac arrhythmias. Chronic severe hypophosphatemia may lead to osteomalacia (bone softening) and bone fractures.
FDA has previously approved other labeling updates for Injectafer that describe this risk. In 2019, FDA determined that ferric carboxymaltose injection can cause serious symptomatic hypophosphatemia. As a result, in February 2020, FDA approved labeling revisions that, along with other changes, added a warning about this risk. In 2023, the warning was revised to include recommendations for serum phosphate level monitoring in patients at risk for hypophosphatemia and in any patient who receives a repeat course of treatment within three months. The revised warning also included osteomalacia and fractures as potential long-term complications and added inflammatory bowel disease as a possible risk factor for hypophosphatemia. In 2025, the warning was further revised to include additional risk factors for hypophosphatemia.
In 2026, FDA conducted an assessment of hypophosphatemia in association with ferric carboxymaltose injection using multiple data sources, including the FDA Adverse Event Reporting System (FAERS) database (which has been incorporated into the FDA Adverse Event Monitoring System [AEMS] database), literature reports, and FDA’s Sentinel System. FDA found that symptomatic hypophosphatemia continues to be reported with ferric carboxymaltose injection and serum phosphate testing levels are low despite labeling changes in February 2020 and May 2023.
PFAS in Medical Devices: What You Need to Know
https://www.fda.gov/medical-devices/products-and-medical-procedures/pfas-medical-devices-what-you-need-know?utm_medium=email&utm_source=govdelivery
The U.S. Food and Drug Administration has updated its webpage about PFAS (per- and polyfluoroalkyl substances) in medical devices to include new Frequently Asked Questions (FAQs) to help consumers understand what these materials are, why they are used, and how the FDA evaluates the safety and effectiveness of devices that contain these materials.
The webpage explains:
Fluoropolymers used in medical devices differ from those identified as potentially presenting health concerns for people in other contexts
Certain fluoropolymers are critical components of life-saving medical devices, including catheters, cardiovascular implants, and wound dressings
Sports Unite Doctors in Spain and Beyond Laura Clavijo Villagrasa
https://www.medscape.com/viewarticle/sports-unite-doctors-spain-and-beyond-2026a1000uop
From the soccer fields of Tarragona, Spain, to the roads of Córdoba, sports have become a key gathering point for healthcare professionals in Spain and beyond. Following the recent victory of the Metges de Tarragona Soccer Club — the medical soccer team of the Tarragona physicians’ association in Spain — in Spain’s 23rd National Medical Soccer Championship, which secured a berth in the 2027 World Medical Football Championship (WMFC) in Torrevieja, Spain, the article highlights a growing calendar of medical sports events. From soccer to cycling, these competitions underscore how teamwork and fair play can improve quality of life for clinicians while turning on-field camaraderie into a valuable support network for everyday medical practice.
Social Egg Freezing in the Spotlight: Choice, Business, or Burden? Roberta Villa, MD
https://www.medscape.com/viewarticle/social-egg-freezing-spotlight-choice-business-or-burden-2026a1000tqd
US congresswoman Alexandria Ocasio-Cortez revealed that, at 36, she has decided to freeze her eggs. In an online social media video, she brought the issue of social egg freezing back to the spotlight. The term refers to the cryopreservation of eggs for nonmedical reasons, allowing women to postpone pregnancy until they feel more personally ready, find the right person to raise a child, or achieve greater financial or professional stability.